Formulation, Development And Characterization Of Nanostructured Lipid Carriers For Exemestane
Main Article Content
Abstract
Aim & Objective: This study aimed to formulate, develop and characterize nanostructured lipid carriers (NLCs) for delivering exemestane (EXE), a BCS Class-IV anticancer drug with poor bioavailability, to enhance its therapeutic efficacy.
Methods: NLCs formulated using melt emulsification with cetylpalmitate (solid lipid), almond oil (liquid lipid), cetyl alcohol (surfactant). Developed formulations were tested for appearance, pH, entrapment efficiency, particle size, polydispersity index (PI), zeta potential, in vitro diffusion, and stability.
Results: All formulated NLCs appeared as milky white dispersions with a pH of 4-5. Entrapment efficiency for EXE ranged from 59.64% to 80.82%, with NLCEXE2 showing the highest at 80.82%. Particle sizes ranged from 79.90 nm to 694.00 nm; NLCEXE2 had a size of 103.30 nm and a PI of 0.409. Its zeta potential was -32.54 mV, indicating stability. NLCEXE2 had the highest diffusion efficiency (88.42%), while NLCEXE7 had the lowest (60.14%) over 12 hours. Stability studies confirmed that NLCEXE2 maintained its quality over 6 months.
Conclusion: This research highlights NLCs potential as a delivery system for poorly soluble drugs like exemestane, improving therapeutic efficacy. Further research and clinical trials are needed to confirm these findings and facilitate practical applications.
Article Details
References
Amaral C, Correia-da-Silva G, Almeida CF, Valente MJ, Varela C, Tavares-da-Silva E, Vinggaard AM, Teixeira N, Roleira FMF. An exemestane derivative, oxymestane-D1, as a new multi-target steroidal aromatase inhibitor for estrogen receptor-positive (ER+) breast cancer: effects on sensitive and resistant cell lines. Molecules. 2023;28:789. https://doi.org/10.3390/molecules28020789
Exemestane drug profile [Internet]. Available from: https://go.drugbank.com/drugs/DB00990
Rizwanullah M, Perwez A, Alam M, Ahmad S, Mir S, Rizvi M, Amin S. Polymer-lipid hybrid nanoparticles of exemestane for improved oral bioavailability and anti-tumor efficacy: an extensive preclinical investigation. Int J Pharm. 2023;642:123136.
Khan S, Sharma A, Jain V. An overview of nanostructured lipid carriers and its application in drug delivery through different routes. Adv Pharm Bull. 2023 Jul;13(3):446-60.
Garg J, Pathania K, Sah SP, et al. Nanostructured lipid carriers: a promising drug carrier for targeting brain tumours. Futur J Pharm Sci. 2022;8:25. https://doi.org/10.1186/s43094-022-00414-8
Kanojia N, Sharma, Gupta N, Singh S. Applications of nanostructured lipid carriers: recent advancements and patent review. Biointerface Res Appl Chem. 2022;12:638-52.
Kassem A, Abbas L, Coutinho O, Opara S, Najaf H, Kasperek D, Pokhrel K, Li X, Tiquia-Arashiro S. Applications of Fourier transform-infrared spectroscopy in microbial cell biology and environmental microbiology: advances, challenges, and future perspectives. Front Microbiol. 2023 Nov 21;14:1304081.
Venkata Ramana P, Rama Krishna Y, Chandra Mouli K. Experimental FT-IR and UV–Vis spectroscopic studies and molecular docking analysis of anti-cancer drugs exemestane and pazopanib. J Mol Struct. 2022;1263:133051. https://doi.org/10.1016/j.molstruc.2022.133051
Kim MH, Kim KT, Sohn SY, Lee JY, Lee CH, Yang H, Lee BK, Lee KW, Kim DD. Formulation and evaluation of nanostructured lipid carriers (NLCs) of 20(S)-protopanaxadiol (PPD) by Box-Behnken design. Int J Nanomedicine. 2019 Oct 25;14:8509-20.
Salunkhe SS, Bhatia NM, Pokharkar VB, Thorat JD, Bhatia MS. Topical delivery of idebenone using nanostructured lipid carriers: evaluations of sun-protection and anti-oxidant effects. J Pharm Investig. 2013;43(4):287-303.
Ebtavanny T, Soeratri W, Rosita N. Effect of lipid composition on nanostructured lipid carrier (NLC) on ubiquinone effectiveness as an anti-aging cosmetic. Int J Drug Delivery Technol. 2018;8(10):252-58.
Bondì ML, Craparo EF, Giammona G, Cervello M, Azzolina A, Diana P, Cirrincione G. Nanostructured lipid carriers-containing anticancer compounds: preparation, characterization, and cytotoxicity studies. Drug Deliv. 2007;14(2):61-7. https://doi.org/10.1080/10717540600739914
Moin A, Deb TK, Osmani RA, Bhosale RR, Hani U. Fabrication, characterization, and evaluation of microsponge delivery system for facilitated fungal therapy. J Basic Clin Pharm. 2016 Mar;7(2):39-48.
Orlu M, Cevher E, Araman A. Design and evaluation of colon-specific drug delivery system containing flurbiprofen microsponges. Int J Pharm. 2006;318:103-17.
Pawar AP, Gholap AP, Kuchekar AB, Bothiraja C, Mali AJ. Formulation and evaluation of optimized oxybenzone microsponge gel for topical delivery. J Drug Deliv. 2015;2015:261068.
Zaki Rizkalla CM, Latif Aziz R, Soliman II. In vitro and in vivo evaluation of hydroxyzine hydrochloride microsponges for topical delivery. AAPS PharmSciTech. 2011;12:989-1001.
Kumari K, Sachan AK, Singh S, Kapoor A. Formulation and evaluation of nanostructured lipid carrier for the management of psoriasis. Int J Pharm Sci & Res. 2021;12(6):3381-90.
Nerli GM, Gonçalves LMD, Cirri M, Almeida AJ, Maestrelli F, Mennini N, Mura PA. Design, evaluation, and comparison of nanostructured lipid carriers and chitosan nanoparticles as carriers of poorly soluble drugs to develop oral liquid formulations suitable for pediatric use. Pharmaceutics. 2023;15:1305.
Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56:1257-72.
Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47:165-96.
ICH Guidelines. ICH Q1A(R2): Stability Testing of New Drug Substances and Products. International Conference on Harmonisation; 2003. Available from: ICH Official Website.
Jenning V, Thunemann AF, Gohla SH. Characterization of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm. 2000;199:167-77.